GMTX Key Statistics, Chart & Performance
The current stock price of GMTX is 1.35 USD. In the past month the price decreased by -21.51%. In the past year, price decreased by -53.61%.
GMTX Latest News, Press Relases and Analysis
GMTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About GMTX
Company Profile
Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2020-08-12. The firm is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The firm's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH to construct that express GEM103 continuously at a therapeutic level. Its pipeline is designed to develop treatments for genetically subpopulations of patients suffering from dry AMD and linked diseases. The firm do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.
Company Info
GEMINI THERAPEUTICS INC
300 One Kendall Square, 3Rd Floor, Suite 4500
Cambridge MASSACHUSETTS 94111 US
CEO: Jason Meyenburg
Employees: 31
Phone: 16174014400.0
GEMINI THERAPEUTICS INC / GMTX FAQ
What does GEMINI THERAPEUTICS INC do?
Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2020-08-12. The firm is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The firm's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH to construct that express GEM103 continuously at a therapeutic level. Its pipeline is designed to develop treatments for genetically subpopulations of patients suffering from dry AMD and linked diseases. The firm do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.
What is the current price of GMTX stock?
The current stock price of GMTX is 1.35 USD.
Does GMTX stock pay dividends?
GMTX does not pay a dividend.
What is the ChartMill rating of GEMINI THERAPEUTICS INC stock?
GMTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for GMTX stock?
6 analysts have analysed GMTX and the average price target is 1.53 USD. This implies a price increase of 13.33% is expected in the next year compared to the current price of 1.35.
What is the next earnings date for GMTX stock?
GEMINI THERAPEUTICS INC (GMTX) will report earnings on 2023-03-08.
GMTX Technical Analysis
GMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GMTX. While GMTX has a great health rating, there are worries on its profitability.
GMTX Financial Highlights
Over the last trailing twelve months GMTX reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS increased by 29.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
GMTX Forecast & Estimates
6 analysts have analysed GMTX and the average price target is 1.53 USD. This implies a price increase of 13.33% is expected in the next year compared to the current price of 1.35.